Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07195721 · ClinicalTrials.gov registry record

The Effect of PROSE or Scleral Lenses on Mental Health

A clinical trial of Depression - Major Depressive Disorder, sponsored by Boston Sight.

Recruiting
Registry status
200
Enrollment target
1
Study location

NCT07195721: Recruiting study of Depression - Major Depressive Disorder, sponsored by Boston Sight.

NCT07195721 is a study of Depression - Major Depressive Disorder that is actively recruiting participants, run by Boston Sight. The registered enrollment target is 200 participants, above the 92-participant average among 19 other Depression - Major Depressive Disorder trials with a reported enrollment target (117% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07195721, a study of Depression - Major Depressive Disorder, is actively recruiting participants, sponsored by Boston Sight.

RECRUITING
Registry status
200 participants
Enrollment target
1
Study location

Study Summary

The goal of this prospective clinical trial is to evaluate the effect that prosthetic replacement of the ocular surface ecosystem (PROSE, BostonSight, Needham MA) treatment may have on mental health, particularly affective mood disorders. Correlation between changes in mental health and ocular symptom improvement and/or visual function improvement will be evaluated.

Primary Outcome

The nine-item Patient Health Questionnaire (PHQ-9) is a depressive symptom scale and diagnostic tool introduced in 2001 to screen adult patients in primary care settings. The instrument assesses for the presence and severity of depressive symptoms and a possible depressive disorder. The minimum score on the PHQ9 is 0 and the maximum score is 27 which indicates the most severe depression.

Study Locations (1)

Massachusetts

  • BostonSight - Needham

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2024-11-11
Est. Completion 2029-10-31
Boston Sight

4 total trials

What NCT07195721 shows while recruiting

NCT07195721 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 92-participant average among 19 other Depression - Major Depressive Disorder trials with a reported enrollment target (117% higher).

The record links to 1 condition, with Depression - Major Depressive Disorder appearing as the primary indexed condition, and to 0 interventions.

NCT07195721 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT07195721 about?

NCT07195721 is a clinical study titled "The Effect of PROSE or Scleral Lenses on Mental Health". The goal of this prospective clinical trial is to evaluate the effect that prosthetic replacement of the ocular surface ecosystem (PROSE, BostonSight, Needham MA) treatment may have on mental health, particularly affective mood disorders. Correlation between changes in mental health and ocular sympt...

What is the current status of trial NCT07195721?

This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2024-11-11. Estimated completion is 2029-10-31.

What conditions does trial NCT07195721 study?

This clinical trial studies the following conditions: Depression - Major Depressive Disorder.

Who is sponsoring clinical trial NCT07195721?

This trial is sponsored by Boston Sight, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07195721 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Depression - Major Depressive Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07195721's enrollment target sits among peer trials

200 4th of 19 higher than 16 of 19 other Depression - Major Depressive Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Depression - Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00107289 · 200 participants · Phase 2

    Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

  • NCT00109174 · 200 participants · NA

    MRS Measurement of Glutamate and GABA Metabolism in Brain

  • NCT00177268 · 200 participants

    Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

  • NCT00493688 · 200 participants

    A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07195721, the US trial registry maintained by the National Library of Medicine. NCT07195721 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.